Decision Biomarkers | GenomeWeb

Decision Biomarkers

Movers & Shakers

Premium

Glenn Barney, Dario Alessi, Philip Cohen, Stephane Bancel, Noubar Afeyan

Avantra was founded last year by Courtagen Capital Group to commercialize the assets of Decision Biomarkers, a protein biomarker technology firm that shuttered its business and filed for Chapter 7 bankruptcy in December 2009.

The company is being launched by Courtagen Capital Group using assets from defunct biotech firm Decision Biomarkers, which Courtagen purchased in bankruptcy court last December.

The demise of Perlegen Sciences and Decision Biomarkers adds two more names to a growing list of array-related firms and businesses that have gone belly up or have been shuttered in the past few years.

The company, formed in 2003, had raised at least $15.1 million in financing in its history, but in its bankruptcy filing said that its liabilities were at least 20 times that of its assets.

The Waltham, Mass.-based biomarker-detection company ceased operations and filed for Chapter 7 bankruptcy last month.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.